FENC Fennec Pharmaceuticals Inc
Price (delayed)
$5.94
Market cap
$163.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.02
Enterprise value
$155.34M
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation
Highlights
The company's EPS has surged by 97% YoY and by 50% QoQ
FENC's debt is down by 39% since the previous quarter and by 39% year-on-year
FENC's revenue has soared by 124% YoY but it is down by 3.7% from the previous quarter
The gross profit has soared by 122% YoY but it has contracted by 3.9% from the previous quarter
Key stats
What are the main financial stats of FENC
Market
Valuations
Earnings
Shares outstanding
27.59M
Market cap
$163.91M
Enterprise value
$155.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.41
EV/EBIT
38.86
EV/EBITDA
38.86
EV/Sales
3.27
Revenue
$47.54M
Gross profit
$44.35M
Operating income
$2.57M
Net income
-$436,000
EBIT
$4M
EBITDA
$4M
Free cash flow
$26.98M
Per share
Balance sheet
Liquidity
EPS
-$0.02
EPS diluted
-$0.02
Free cash flow per share
$0.99
Book value per share
-$0.21
Revenue per share
$1.74
TBVPS
$1.65
Total assets
$44.95M
Total liabilities
$50.82M
Debt
$18.07M
Equity
-$5.87M
Working capital
$37.21M
Debt to equity
-3.08
Current ratio
6.38
Quick ratio
5.71
Net debt/EBITDA
-2.14
Margins
Efficiency
Dividend
EBITDA margin
8.4%
Gross margin
93.3%
Net margin
-0.9%
Operating margin
5.4%
Return on assets
-0.7%
Return on equity
N/A
Return on invested capital
10.6%
Return on capital employed
10.5%
Return on sales
8.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FENC stock price
How has the Fennec Pharmaceuticals stock price performed over time
Intraday
7.41%
1 week
-8.19%
1 month
-15.38%
1 year
-45.95%
YTD
-6.01%
QTD
-2.46%
Financial performance
How have Fennec Pharmaceuticals's revenue and profit performed over time
Revenue
$47.54M
Gross profit
$44.35M
Operating income
$2.57M
Net income
-$436,000
Gross margin
93.3%
Net margin
-0.9%
FENC's revenue has soared by 124% YoY but it is down by 3.7% from the previous quarter
The gross profit has soared by 122% YoY but it has contracted by 3.9% from the previous quarter
The operating income has soared by 120% YoY and by 52% QoQ
Fennec Pharmaceuticals's operating margin has soared by 109% YoY and by 59% from the previous quarter
Growth
What is Fennec Pharmaceuticals's growth rate over time
Valuation
What is Fennec Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.41
EV/EBIT
38.86
EV/EBITDA
38.86
EV/Sales
3.27
The company's EPS has surged by 97% YoY and by 50% QoQ
The equity has grown by 49% YoY but it has contracted by 14% from the previous quarter
FENC's revenue has soared by 124% YoY but it is down by 3.7% from the previous quarter
The P/S is 22% lower than the last 4 quarters average of 4.1
Efficiency
How efficient is Fennec Pharmaceuticals business performance
The return on invested capital has surged by 126% year-on-year and by 9% since the previous quarter
The company's return on sales has surged by 114% YoY and by 9% QoQ
The return on assets has surged by 99% year-on-year but it has dropped by 75% since the previous quarter
Dividends
What is FENC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FENC.
Financial health
How did Fennec Pharmaceuticals financials performed over time
The total assets is 12% less than the total liabilities
The quick ratio has soared by 96% YoY but it has contracted by 20% from the previous quarter
FENC's current ratio has soared by 79% year-on-year but it is down by 18% since the previous quarter
The equity has grown by 49% YoY but it has contracted by 14% from the previous quarter
The company's debt to equity rose by 47% QoQ but it fell by 20% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.